IL6 and osteosarcoma: To assess the potential role of IL-6 in the process of lobaplatin resistance in osteosarcoma cells, 60 ng/mL rhIL-6 was applied to SaOS-2 and SOSP-9607 osteosarcoma cells 8 h before lobaplatin treatment.